Can You Take Spravato With Other Depression Medications?
Most patients who qualify for Spravato are already taking something for depression. That is actually part of the clinical picture. Spravato is approved for treatment-resistant depression, which by definition means standard antidepressants have not worked well enough on their own.
So the question of combining Spravato with other medications is not just common. It is clinically relevant for nearly every patient who considers this treatment. The honest answer is nuanced. Some combinations are used intentionally as part of an FDA-approved treatment approach. Others require careful clinical review before proceeding. And a few carry interaction risks worth understanding before your first session. This guide covers what patients should know before and during Spravato treatment regarding their existing medication regimen.
How Spravato Is Designed to Work Alongside Antidepressants
Spravato is not designed to replace oral antidepressants. The FDA-approved protocol for treatment-resistant depression actually requires that Spravato be used in conjunction with an oral antidepressant, not instead of one. This is an important clinical distinction. Patients approved for this indication continue their existing antidepressant or start a new one alongside Spravato. The combined approach is part of the approved treatment framework, not an exception to it.
For patients approved for the second indication, depressive symptoms in major depressive disorder with acute suicidal ideation or behavior, the same principle applies. Spravato is used alongside oral antidepressant treatment, not as a standalone intervention. Understanding this from the start helps patients approach the question of Spravato with other medications from the right clinical foundation.
Why Medication Review Matters Before Starting Spravato
Every patient starting Spravato treatment undergoes a full medication review as part of the eligibility evaluation. This step is not administrative. It is a clinical necessity. Certain medications interact with esketamine in ways that affect either safety or treatment response. Others may amplify specific side effects. A provider who does not conduct a thorough medication review before recommending Spravato is not operating with adequate clinical information.
Bring a complete and accurate medication list to your evaluation. Include prescription medications, over-the-counter products, and any supplements. Dosages and timing matter as much as the names of what you are taking. For more on what the evaluation process involves, visit our page on Spravato esketamine treatment at Allay.
Medications That Require Careful Clinical Review
Several medication categories carry specific considerations when combined with Spravato. Patients should be aware of these categories before their evaluation so they can provide complete and accurate information to their provider.
CNS Depressants and Sedating Medications
Combining Spravato with other medications that cause sedation requires careful clinical evaluation. The interaction between these categories shapes how providers approach dosing, monitoring, and session scheduling.
Benzodiazepines. Medications like lorazepam, clonazepam, and alprazolam are central nervous system depressants. When used alongside Spravato, they may intensify sedative effects. Providers review current benzodiazepine use carefully before proceeding. Timing of these medications on session days is particularly relevant.
Sleep aids and sedating antihistamines. Over-the-counter sleep products and prescription sedative-hypnotics fall into a similar category. Even products that feel mild can compound the sedation Spravato produces. Disclosing these to your provider matters regardless of how infrequently you use them.
Opioids. Patients managing chronic pain with opioid medications carry additional interaction considerations. The combination of opioid sedation with Spravato’s effects requires specific clinical assessment. Providers weigh this carefully as part of the eligibility review process.
Muscle relaxants. Certain muscle relaxants produce CNS depression that interacts with esketamine. Patients taking these for pain or spasm should disclose them during evaluation, even if they do not consider them psychiatric medications.
Monoamine Oxidase Inhibitors
MAOIs represent one of the more significant interaction categories for patients considering Spravato with other medications. This class includes older antidepressants like phenelzine, tranylcypromine, and selegiline.
MAOIs affect how the body processes certain neurotransmitters. Combining them with esketamine carries specific risks that providers must evaluate before treatment begins. Patients who are currently taking or have recently taken an MAOI should disclose this immediately during their evaluation.
Switching from an MAOI to a different antidepressant before starting Spravato requires a washout period. The length of that period depends on which MAOI was used. A licensed provider determines the appropriate timeline based on your specific medication history.
Stimulants and Psychostimulant Medications
Patients taking stimulant medications for ADHD or other conditions should disclose these during evaluation. Stimulants and esketamine work through different neurological pathways, but their combined cardiovascular effects warrant clinical review.
Spravato can temporarily increase blood pressure. Certain stimulant medications carry similar cardiovascular effects. A provider reviewing this combination will assess your baseline cardiovascular health and monitor blood pressure more closely during sessions if both are present.
This does not necessarily mean stimulant use disqualifies a patient from Spravato. It means providers need the full picture to monitor appropriately.
Medications That Are Commonly Continued During Spravato Treatment
Not every medication combination requires significant clinical concern. Many patients take Spravato with other medications that are routinely continued during treatment with appropriate provider oversight. Here is what commonly continues without major adjustment for most patients.
- SSRIs and SNRIs such as sertraline, escitalopram, duloxetine, and venlafaxine are frequently continued as the oral antidepressant component of the FDA-approved treatment protocol
- Atypical antipsychotics used as augmentation agents for depression may be continued based on provider assessment of the individual patient’s clinical profile
- Mood stabilizers in patients with bipolar depression require specific clinical evaluation but are not automatically excluded from Spravato treatment
- Non-sedating blood pressure medications in patients with managed hypertension may be continued with closer blood pressure monitoring during sessions
- Thyroid medications for patients with thyroid conditions that contribute to depressive symptoms are typically continued without modification
How Side Effects Change With Combination Treatment
Spravato produces specific side effects that every patient should understand before starting. When combined with other medications, some of these effects may be more pronounced.
Dissociation is the most commonly reported effect. Patients feel temporarily detached from their surroundings during sessions. This is expected and typically resolves within the two-hour monitoring period. Medications that affect perception or sedation may influence the intensity of this experience.
Sedation is another consistent effect of Spravato. The degree of sedation varies by patient. Adding other sedating medications to the picture increases the importance of clinical monitoring during and after each session.
Blood pressure elevation occurs in many patients during Spravato sessions. Cardiovascular medications, stimulants, and certain other drugs interact with this effect. Providers monitor blood pressure at defined intervals during every session for this reason.
Nausea is reported by some patients, particularly earlier in treatment. Certain medications affect gastrointestinal function in ways that may interact with this side effect. Providers can address nausea management strategies during your evaluation.
What Patients Should Tell Their Provider Before Each Session
Medication status can change between appointments. A drug interaction consideration that was not present at your initial evaluation may become relevant later if your medications change.
Before each Spravato session, inform your clinical team about any changes to your medications since your last visit. This includes new prescriptions from other providers, changes in dosage, medications you stopped taking, and any new supplements or over-the-counter products.
This ongoing disclosure is part of responsible combination treatment. Providers cannot monitor what they do not know about. Keeping your clinical team current protects your safety at every stage of treatment.
For information on how Spravato compares to IV ketamine for patients weighing their options, visit our page on Spravato vs. ketamine for depression.
What to Expect at Your Medication Review Appointment
The medication review that precedes Spravato treatment is a structured clinical conversation. Knowing what to bring and what to discuss helps you make the most of that appointment.
- Bring a written medication list with drug names, dosages, prescribing providers, and how long you have been taking each
- Include everything from daily prescriptions to occasional sleep aids to vitamins and herbal supplements
- Note any recent changes including medications started, stopped, or adjusted in the past several months
- Mention all prescribing providers so your Spravato provider can coordinate if needed
- Ask about session-day timing for medications you take daily so you understand how to time them on treatment days
Crisis Resources
If you are experiencing thoughts of self-harm or suicidal ideation, contact the Suicide and Crisis Lifeline immediately by calling or texting 988. Spravato treatment requires scheduling, evaluation, and clinical oversight. It is not a crisis intervention. Immediate support is available right now through the crisis line.
Speak With a Provider at Allay Health and Wellness
Every patient who comes to Allay Health and Wellness for Spravato treatment receives a thorough medication review before any session is scheduled. Our licensed clinical team evaluates the full picture, including how Spravato with other medications you currently take may affect your treatment plan and monitoring needs.
We serve patients in Palm Beach Gardens, West Palm Beach, and surrounding Palm Beach County communities. Coverage may apply for Spravato treatment. Verify with your insurer before beginning care.
Allay Health and Wellness
11000 Prosperity Farms Rd, Suite 101
Palm Beach Gardens, FL 33410
Phone: (561) 421-6444
Email: [email protected]
This content is for educational purposes only and does not constitute medical advice. Spravato is FDA-approved for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. It is not approved for other conditions. Treatment eligibility, drug interactions, outcomes, and side effects vary by individual and require evaluation by a licensed healthcare provider. No outcomes are guaranteed. If you are in crisis, call or text 988.
